• Skip to primary navigation
  • Skip to main content

Virtual IMMUNOLOGY2021™

May 10 - 15, 2021

  • Program
    • Monday, May 10
    • Tuesday, May 11
    • Wednesday, May 12
    • Thursday, May 13
    • Friday, May 14
    • Saturday, May 15
  • Abstracts
    • Submission Guidelines
    • Topic Categories
    • Editing or Withdrawing an Abstract
    • Abstract Publication and Citation
    • ePoster Presentation Guidelines
  • Registration
    • Code of Conduct
  • Awards
    • Career Awards
    • Meeting Awards
  • Careers
    • Jobs Board
  • Exhibitors
  • Sponsors
  • Show Search
Hide Search

Michael J. Lenardo

NIAID, NIH

Michael Lenardo

Michael J. Lenardo, M.D., NIAID, NIH, is the recipient of the 2020 AAI-Steinman Award for Human Immunology Research. He is recognized for his molecular characterization of primary immune disorders, resulting in new understanding of signaling pathways and novel successful treatments for patients.

Dr. Lenardo showed that activated T cells undergo programmed cell death upon T cell receptor restimulation and described the role of apoptosis in antigen-induced tolerance. He and his collaborators further demonstrated that dominant-negative mutations in the TNF-receptor Fas and resulting defects in lymphocyte apoptosis caused autoimmune lymphoproliferative syndrome.

This discovery provided confirmation of the role of Fas in peripheral tolerance and advanced understanding of the way Fas and TNF receptors signal. These studies broadened to describe other immune disorders caused by mutations of FasL, N-Ras, caspase-8, caspase-10, and others, and continued to provide mechanistic insight. His work defined a role for caspase-8 in lymphocyte activation via NF-κB activation and for CARD11 in B cell lymphocytosis.

Lenardo has not only described mutations in immunodeficiencies but has applied this knowledge to develop new therapeutic approaches. His laboratory demonstrated that mutations of the MAGT1 magnesium transporter were the cause of a novel primary immunodeficiency (XMEN) characterized by the inability to respond to Epstein-Barr virus. This discovery illuminated the role of magnesium flux in T cell activation and spurred the use of magnesium supplementation as a successful treatment for this disease. The description by Lenardo and his collaborators of activating mutations affecting PI3 kinase delta in an immunodeficiency (PASLI) associated with lymphoproliferation and T cell senescence led to promising clinical trials of PI3 kinase delta inhibitors for these patients. His discovery of CD55 deficiency as the cause for a lethal protein-losing enteropathy and thrombosis syndrome (CHAPLE) led to the successful use of a complement inhibitor as a long-term treatment.

Jean-Laurent Casanova, HHMI, investigator, professor, and head of the St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller University, says, “A very specific feature of Dr. Lenardo’s work has been its direct therapeutic impact. Mike used his discoveries in pathogenesis to treat patients with new approaches based on a rational understanding of the disease mechanisms. His patient-based research is unique and has always been at the forefront of the field.”

Lenardo’s colleagues further laud his commitment to mentoring. Raif Geha, James L. Gamble Professor of Pediatrics, Harvard Medical School, Boston Children’s Hospital, states, “His work is rigorous, substantive, creative, and well-respected in the field. Moreover, it is clear that he endeavors to pass along these qualities and his overall approach to science to those whom he mentors.”

Lenardo has trained more than 50 students and fellows, many of whom have gone on to leadership positions in academia, government, and industry. He also founded the NIH-Oxford-Cambridge Scholars Ph.D. program that has fostered international collaboration in student training through a dual-mentored Ph.D. with advisors at NIH and either Oxford or Cambridge in the United Kingdom.

Lenardo received his M.D. from Washington University School of Medicine, St. Louis. Following postdoctoral training at the University of Iowa and Massachusetts Institute of Technology, he joined the Laboratory of Immunology at NIAID as an investigator. He currently holds the positions of senior investigator and chief of the Molecular Development of the Immune System Section, chief of the Clinical and Molecular Genomics Unit, and director of the NIAID Clinical Genomics Program.

Lenardo is an elected member of the National Academy of Sciences and National Academy of Medicine, and a Fellow of the American Academy of Arts and Sciences. His honors include the NIH MERIT Award (awarded four times), NIH Director’s Award (awarded three times), and the NIH Clinical Center Director’s Award.

An AAI member since 1993, Lenardo has served as a lecturer at the AAI Introductory Course in Immunology and as a major symposium chair and speaker at the AAI annual meeting.

Discover more


AAI Logo

Not a Member?

Join AAI Now!

Footer

Virtual
IMMUNOLOGY2021™

May 10—15, 2021

Copyright © 2025 The American Association of Immunologists, Inc.

  • Facebook
  • LinkedIn
  • Twitter
  • Code of Conduct
  • Privacy Policy
  • Press Policy
We use cookies on this site to enhance your user experience. We do not store personal data in cookies. For more information about the use of cookies on this site, please review our Privacy Policy page. I Understand
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
Meeting Awards

Meeting awards are closed.

Philadelphia Hotels

Hotel booking will be available in July 2020.

Check back frequently for updates.

Abstract Submission

Abstract submission is closed.

Late-breaking abstract submission opens February 9.